Chattem Ban Antiperspirant Divestiture To Fund New OTC Acquisitions
This article was originally published in The Tan Sheet
Executive Summary
Chattem will use the bulk of proceeds from the Ban antiperspirant line divestiture to Andrew Jergens to fund OTC acquisitions better suited to its "niche" product portfolio, the company said Aug. 24.